IBRX – immunitybio, inc. (US:NASDAQ)
Stock Stats
News
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week [Seeking Alpha]
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe [Yahoo! Finance]
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Form 8-K ImmunityBio, Inc. For: Dec 12
Form SCHEDULE 13D/A ImmunityBio, Inc. Filed by: Cambridge Equities, LP
Form 8-K ImmunityBio, Inc. For: Nov 04
Form 10-Q ImmunityBio, Inc. For: Sep 30
Form DEF 14C ImmunityBio, Inc. For: Oct 20
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.